241,188 Shares in BioXcel Therapeutics, Inc. $BTAI Bought by Oaktree Capital Management LP

Oaktree Capital Management LP purchased a new stake in BioXcel Therapeutics, Inc. (NASDAQ:BTAI) in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 241,188 shares of the company’s stock, valued at approximately $437,000. Oaktree Capital Management LP owned about 3.98% of BioXcel Therapeutics at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of BTAI. XTX Topco Ltd purchased a new position in shares of BioXcel Therapeutics during the second quarter worth about $42,000. Geode Capital Management LLC boosted its position in shares of BioXcel Therapeutics by 27.7% in the 2nd quarter. Geode Capital Management LLC now owns 28,182 shares of the company’s stock valued at $51,000 after purchasing an additional 6,120 shares during the period. Goldman Sachs Group Inc. purchased a new position in BioXcel Therapeutics during the 1st quarter worth approximately $50,000. Finally, Murchinson Ltd. acquired a new position in BioXcel Therapeutics during the first quarter worth approximately $276,000. Institutional investors and hedge funds own 30.68% of the company’s stock.

BioXcel Therapeutics Trading Up 9.4%

NASDAQ:BTAI opened at $2.09 on Friday. BioXcel Therapeutics, Inc. has a 12-month low of $1.17 and a 12-month high of $9.26. The stock’s 50 day simple moving average is $2.17 and its 200-day simple moving average is $2.49. The firm has a market cap of $45.71 million, a P/E ratio of -0.22 and a beta of 0.21.

BioXcel Therapeutics (NASDAQ:BTAI) last issued its quarterly earnings results on Wednesday, November 12th. The company reported ($2.18) earnings per share for the quarter, missing the consensus estimate of ($1.54) by ($0.64). The company had revenue of $0.10 million during the quarter, compared to analysts’ expectations of $0.20 million. Research analysts forecast that BioXcel Therapeutics, Inc. will post -24.39 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on BTAI shares. HC Wainwright reiterated a “buy” rating and issued a $10.00 price objective on shares of BioXcel Therapeutics in a research note on Monday, September 15th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of BioXcel Therapeutics in a report on Wednesday, October 8th. Finally, Zacks Research downgraded shares of BioXcel Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, August 26th. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, BioXcel Therapeutics has an average rating of “Hold” and an average price target of $39.75.

BioXcel Therapeutics Company Profile

BioXcel Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices.